Advertisement
Most lung and colorectal cancer patients involve family members in treatment decisions

Most Cancer Patients Involve Family in Treatment Decisions

0
Chinese-speaking Asians, Spanish-speaking Hispanics more often share decisions with family
In accordance with the changes in graduate medical education to better prepare doctors for a changing health care system

Changes Being Made to Med School Applicant Assessment

0
New skills being emphasized on MCAT; multiple mini-interview technique being adopted
The U.S. Food and Drug Administration has approved Zarxio (filgrastim-sndz)

FDA Approves First Biosimilar Drug in U.S.

0
Zarxio is highly similar to long-sanctioned cancer drug
For patients with breast cancer

Goserelin Protects Against Ovarian Failure in Breast Cancer

0
Randomized trial shows reduction in ovarian failure and more pregnancy for chemo + goserelin
A mobile phone application has been released to identify current drug shortages

FDA Launches First App to Identify Drug Shortages

0
App IDs shortages, resolved shortages, product discontinuation; can be used to report shortages
For patients with atrial fibrillation receiving anticoagulant treatment

Anemia Linked to Adverse Outcomes in Atrial Fibrillation

0
Increased risk of thromboembolic events, bleeding complications, mortality during anticoagulant tx
For patients with advanced-stage esophageal squamous cell carcinoma

HPV-16 Tied to Improved Survival in Advanced Esophageal Cancer

0
Improved survival and treatment response for HPV-16 positive patients
Rush University Medical Center's website has started adding the results of patient surveys to individual physician profiles

Rush University Adds Patient Scores to Doctor Profiles

0
Scores based on 30 or more patient surveys completed in one-year period
Use of localized correlated spectroscopy shows significant changes in women with BRCA1 and BRCA2 mutations

Correlated Spectroscopy IDs Changes in BRCA1/2 Carriers

0
Lipid and metabolite deregulation seen in breast tissue of women carrying BRCA1/2 mutations
U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small-cell lung cancer

FDA: Opdivo Approval Expanded to Include Lung Cancer

0
FDA approves drug for NSCLC patients who have been treated with platinum-based chemotherapy